The Washington Post  |  December 10, 2020

A critical issue will be the longer-term safety program the FDA and Pfizer have set up to ensure they catch any serious complications caused by the vaccine after it is on the market. “Once you roll something out to hundreds of thousands and millions of people, safety problems can emerge,” said Lawrence Gostin, a public health expert at Georgetown Law School.

Read more here.